Stéphanie Lheureux, MD, PhD

Dr. Lheureux is a Clinician Investigator in the Bras Drug Development Program, Staff Medical Oncologist and Gynecology Site Leader at Princess Margaret Cancer Centre. She is also an Assistant Professor at the University of Toronto.

Following her Medical Degree and specialization in Medical Oncology (University of Caen, France) she was recruited as an Assistant Professor at the Academic Cancer Center of Caen (Normandy, France), where her practice combined research and clinical care in gynecologic cancers. Shortly thereafter, Dr. Lheureux received her PhD with merit for preclinical evaluation of new targeted therapies and drug resistance mechanisms in ovarian cancer. She worked on new treatment to overcome chemoresistance in ovarian cancer models including an imaging component. Based on her project findings, she designed a phase II clinical trial of with integrated correlatives studies in platinum-resistant ovarian cancer led by GINECO (NCT#02591095), the French arm of the Gynaecologic Cancer InterGroup. While she was actively involved in laboratory research, she continued to improve her clinical skillset by participating in the Young Investigators Group of GINECO. To successfully develop an ovarian cancer focused translational research program, she pursued a Clinical Research Fellowship training in the Bras Drug Development Program at Princess Margaret Cancer Centre with an emphasis on Gynecologic Medical Oncology (Supervisor: Dr Amit Oza) and early phase clinical trials (Supervisor: Dr Lillian Siu). Dr. Lheureux then completed additional training in early drug development at the Investigational Drug Branch of CTEP at the National Cancer Institute.

Dr. Lheureux's clinical and research interests are on integrating translational research in early phase gynecologic cancer clinical trials and incorporating these findings into the clinic in a timely manner. She is a principal investigator or sub-investigator for numerous clinical trials in gynecologic cancers at Princess Margaret, a member of the Gynecologic Cancer InterGroup, and co-investigator on several large scale programs supported by the Canadian Cancer Society Research Institute and the Ontario Institute for Cancer Research.

Eur J Cancer. 2017 Oct;84:114-120
Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Methods. 2017 Jul 23;:
Colombo I, Overchuk M, Chen J, Reilly RM, Zheng G, Lheureux S
Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627
Wilson MK, Friedlander ML, Lheureux S, Small W, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM
Expert Opin Biol Ther. 2017 Aug;17(8):927-943
Mandilaras V, Vernon M, Meryet-Figuière M, Karakasis K, Lambert B, Poulain L, Oza A, Denoyelle C, Lheureux S
J Clin Oncol. 2017 Jul 10;35(20):2329-2337
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai...
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):41-54
Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM
Expert Opin Pharmacother. 2017 Apr;18(6):631-640
Kanjanapan Y, Lheureux S, Oza AM
Clin Cancer Res. 2017 Aug 01;23(15):4086-4094
Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW,...
Gynecol Oncol. 2017 Jun;145(3):584-594
Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S
J Clin Oncol. 2017 Apr 10;35(11):1240-1249
Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM